Keyphrases
Atypical Tumors
7%
BCG Shortage
21%
BCG Therapy
7%
BCG+
7%
BCG-unresponsive
21%
BCG-unresponsive Bladder Cancer
7%
BCG-unresponsive Disease
7%
Bladder Biopsy
14%
Bladder Neck
7%
Bladder Trigone
7%
Bladder Tumor
7%
Bladder Washing
7%
Bladder-sparing
7%
Blue Light Cystoscopy
14%
Cancer Induction
7%
Cancer Reporting
7%
Cystoscopy
14%
Depth of Invasion
7%
Detrusor muscle
7%
Device Therapy
7%
Endoscopic Resection
7%
Evaluation Level
7%
Flexible Cystoscope
7%
High-grade T1
7%
High-risk Non-muscle-invasive Bladder Cancer
14%
Histological Variants
7%
Incidental Carcinoma
7%
Initial Workup
7%
Intravesical BCG
21%
Intravesical Chemotherapy
28%
Intravesical Gemcitabine
7%
Intravesical Therapy
14%
Lamina Propria
7%
Limited Supply
7%
Multiple Tumors
14%
N-803
7%
Nadofaragene Firadenovec
7%
Neoadjuvant Cisplatin
7%
Non-muscle Invasive Bladder Cancer (NMIBC)
100%
Pelvic Lymph Node Dissection
7%
Pirarubicin
7%
Planning Levels
7%
Prostatic Duct
7%
Prostatic Urethra
7%
Recurrence Score
7%
Restaging
28%
Single Instillation
28%
Single-agent Chemotherapy
7%
Stage Level
7%
Stromal Invasion
7%
Transurethral Resection
21%
Transurethral Resection of Bladder Tumor (TURBT)
100%
Treatment Adjustment
7%
Tumor Levels
21%
Unresponsive Patients
7%
Upper Tract
7%
Upper Urinary Tract
14%
Urethral Involvement
7%
Urethral mucosa
7%
Urinary Tract Imaging
14%
Variant Histology
7%
White Light Cystoscopy
21%
Medicine and Dentistry
Bladder Biopsy
9%
Bladder Carcinoma
4%
Bladder Irrigation
4%
Bladder Neck
4%
Bladder Trigone
4%
Bladder Tumor
68%
Chemotherapy Agent
4%
Cystoscopy
31%
Detrusor Muscle
4%
Epirubicin
9%
Intravesical Drug Administration
9%
Lamina Propria
4%
Mycobacterium Bovis BCG
100%
Nadofaragene Firadenovec
4%
Narrow Band Imaging
4%
Non Muscle Invasive Bladder Cancer
100%
Non Muscle Invasive Treatment of Bladder Cancer
4%
Oportuzumab Monatox
4%
Pembrolizumab
4%
Pirarubicin
4%
Proteus Syndrome
9%
Upper Urinary Tract
9%